4.38
전일 마감가:
$4.69
열려 있는:
$4.69
하루 거래량:
790.32K
Relative Volume:
0.82
시가총액:
$198.03M
수익:
순이익/손실:
$-85.57M
주가수익비율:
-2.2853
EPS:
-1.9166
순현금흐름:
$-72.14M
1주 성능:
-7.79%
1개월 성능:
-44.20%
6개월 성능:
-89.51%
1년 성능:
-85.06%
Sionna Therapeutics Inc Stock (SION) Company Profile
명칭
Sionna Therapeutics Inc
전화
617-819-2020
주소
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
SION
Sionna Therapeutics Inc
|
4.38 | 198.03M | 0 | -85.57M | -72.14M | -1.9166 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2026-08-10 | 다운그레이드 | Citizens | Mkt Outperform → Mkt Perform |
| 2026-08-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2026-08-10 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2026-08-10 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2026-08-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2026-08-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-05-05 | 개시 | Wedbush | Outperform |
| 2026-02-24 | 개시 | Citizens | Mkt Outperform |
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-04 | 개시 | Guggenheim | Buy |
| 2025-03-04 | 개시 | Stifel | Buy |
| 2025-03-04 | 개시 | TD Cowen | Buy |
모두보기
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc.SION - GlobeNewswire Inc.
Ra Capital Management sells $21.8m in Sionna Therapeutics shares By Investing.com - Investing.com Nigeria
Ra Capital Management sells $21.8m in Sionna Therapeutics shares By Investing.com - Investing.com Canada
RA Capital’s Sionna (NASDAQ: SION) stock sale wasn’t under a preset trading plan - Stock Titan
Sionna Therapeutics (Nasdaq:SION)Stock Analysis - Simply Wall Street
Ra Capital Management sells $21.8m in Sionna Therapeutics shares - Investing.com
Sionna Therapeutics CMO Charlotte McKee Granted RSUs and Stock Option Repricing Announced - Kalkine Media
Sionna (SION) cuts CFO option price to $7.18 - Stock Titan
Sionna Therapeutics (SION) cuts CLO's option price and adds new RSUs - Stock Titan
Sionna Therapeutics (SION) cuts CEO option exercise price - Stock Titan
Sionna Therapeutics, Inc. (SION) Stock Analysis: Unpacking a 192% Potential Upside in the Biotech Space - DirectorsTalk Interviews
Sionna (SION) cuts nearly half its jobs to back one cystic fibrosis program - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc.SION - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc.SION - FinancialContent
Sionna Therapeutics faces securities fraud prob... - Pluang
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Sionna Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sionna Therapeutics, Inc. (SION) And Encourages Shareholders to Reach Out - ACCESS Newswire
SION INVESTIGATION: Investigation Launched into Sionna - GlobeNewswire
Sionna Therapeutics stock plunges 91% after fai... - Pluang
Securities Fraud Investigation Into Sionna Therapeutics, - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc.SION - financialcontent.com
Robbins LLP Reminds Investors it is Investigating Sionna Therapeutics for Potential Securities Violations - GlobeNewswire
Securities Fraud Investigation Into Sionna Therapeutics, - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sionna Therapeutics, Inc. (SION) And Encourages Stockholders to Connect - ACCESS Newswire
Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sionna (SION) Earnings Reading: Profit Per Share Clears Its Benchmark in the Latest Reading; Price Move - vinanet.vn
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - Yahoo Finance
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - The Motley Fool
2026-08-20 | Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:SION | Press Release - Stockhouse
Sionna (SION) Quarterly Figures: The Bottom-Line Figure Beats Its Comparison in the Current Update; Trading Response: The Share Price Adds 5.22% for the Current SessionTangible Book Value - vinanet.vn
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sionna Therapeutics, Inc. (SION) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Sionna shares plunge 92% after Phase 2a trial o... - Pluang
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Sionna Therapeutics (SION) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - Business Wire
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - WBOC TV
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - FinancialContent
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information - Business Wire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Sionna Therapeutics (SION) - GlobeNewswire
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law - lincolnjournal.com
SION INVESTOR ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - The Daily Tribune News
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION) - Business Wire
SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - PR Newswire
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep? - Yahoo Finance
Sionna Therapeutics Inc (SION) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sionna Therapeutics Inc 주식 (SION) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA Capital Healthcare Fund, L. | Director |
Sep 17 '26 |
Proposed Sale |
6.33 |
3,448,811 |
21,834,318 |
0 |
| ORBIMED ADVISORS LLC | Director |
Jul 07 '26 |
Sale |
44.86 |
85,918 |
3,854,281 |
2,469,959 |
| Thompson Peter A. | Director |
Jul 07 '26 |
Sale |
44.86 |
85,918 |
3,854,281 |
2,469,959 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Sale |
43.60 |
10,250 |
446,862 |
0 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
6.11 |
10,250 |
62,628 |
10,250 |
| JENNIFER FITZPATRICK | Officer |
Jul 06 '26 |
Proposed Sale |
43.99 |
10,250 |
450,898 |
0 |
| ORBIMED ADVISORS LLC | Director |
Jun 30 '26 |
Sale |
45.50 |
115,844 |
5,270,902 |
2,555,877 |
| Thompson Peter A. | Director |
Jun 30 '26 |
Sale |
45.50 |
115,844 |
5,270,902 |
2,555,877 |
| OrbiMed Private Investments VI | Shareholder |
May 29 '26 |
Proposed Sale |
42.80 |
1,082,480 |
46,330,144 |
0 |
| Thompson Peter A. | Director |
May 27 '26 |
Sale |
44.49 |
101 |
4,493 |
2,671,721 |
자본화:
|
볼륨(24시간):